Compared with insulin glargine, tirzepatide was associated with significantly less new-onset macroalbuminuria in patients with type 2 diabetes at high cardiovascular risk but mainly normal kidney function.
Sassa spokesperson Paseka Letsatsi acknowledged that the change may cause difficulties but advised affected clients to use other ways to access their funds.